Journal
CLINICAL TRANSPLANTATION
Volume 35, Issue 3, Pages -Publisher
WILEY
DOI: 10.1111/ctr.14199
Keywords
acute; leukemia; outcomes; prognostic factors; relapse; second allogeneic stem cell transplantation
Categories
Funding
- Asan Institute for Life Science and Corporate Relations of Asan Medical Center, Seoul, Korea [2017-199]
- Ulsan University Hospital Research Grant [UUH-2019-06]
Ask authors/readers for more resources
This study evaluated the outcomes of second HSCT in patients with relapsed acute leukemia after allogeneic HSCT in two Korean institutes, showing a 2-year overall survival of 21.0% and event-free survival of 17.5%. Disease status at HSCT2 and remission duration after HSCT1 were identified as independent prognostic factors.
The prognosis of patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation (HSCT) is dismal. We aimed to evaluate the outcomes and prognostic factors of the second HSCT (HSCT2) in acute leukemia patients relapsed after the first HSCT (HSCT1). We analyzed 80 patients who received HSCT2 for relapsed acute leukemia in two Korean institutes. All but four patients received HSCT2 from a donor other than matched sibling donor: an unrelated donor (URD) in 30 and a familial haploidentical donor (FHD) in 46. Forty-four patients (55.0%) were in complete remission (CR) or CR with incomplete count recovery (CRi) at HSCT2, and the median time from HSCT1 to relapse was 9 months. The 2-year overall survival (OS) and event-free survival (EFS) were 21.0% and 17.5%, respectively. The outcomes were similar between URD and FHD. Multivariate analysis demonstrated that disease status (active disease vs. CR/CRi) at HSCT2 and remission duration after HSCT1 were independent prognostic factors for OS and EFS after HSCT2. HSCT2 from URD or FHD was feasible in patients with acute leukemia relapsed after allogeneic HSCT. Also, our study confirmed two critical prognostic factors; disease status at HSCT2 and remission duration after HSCT1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available